GRCE
NASDAQGrace Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings1
News · 26 weeks22+75%
2026-03-012026-08-23
Mix1690d
- SEC Filings11(69%)
- Other3(19%)
- Offering1(6%)
- Insider1(6%)
Latest news
25 items- SECSEC Form S-3 filed by Grace Therapeutics Inc.S-3 - Grace Therapeutics, Inc. (0001444192) (Filer)
- INSIDERLarge owner Opaleye Management Inc. bought $24,206 worth of shares (11,608 units at $2.09) (SEC Form 4)4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdatePRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026. "We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104," said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. "As previously disclosed, the U.S. Food and Drug Administration’s (FDA) Compl
- SECSEC Form 10-Q filed by Grace Therapeutics Inc.10-Q - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces $10 Million Private PlacementPRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) ("Grace Therapeutics" or "the Company"), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase agreement for a private placement financing with new and existing fundamental investors. The financing is expected to result in aggregate gross proceeds to the Company of approximately $10 million, before deducting placement agent fees and other offering expenses. The Company intends to use the ne
- SECSEC Form DEFA14A filed by Grace Therapeutics Inc.DEFA14A - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECSEC Form DEF 14A filed by Grace Therapeutics Inc.DEF 14A - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug AdministrationFDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRINCETON, N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Comp
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business UpdateType A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDAResubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the f
- SECSEC Form 10-K filed by Grace Therapeutics Inc.10-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Grace Therapeutics Inc.SCHEDULE 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit Application Following Resolution of Cited Items PRINCETON, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administ
- PRGrace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract highlighting the results from the Company's STRIVE-ON Phase 3 Safety Trial has been accepted for presentation at the upcoming 2026 American Academy of Neurology annual meeting, to be held April 18-22, 2026 in Chicago, IL. The STRIVE-ON Trial results will be presented as a poster on A
- PRGrace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical ConferencesPRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that abstracts discussing the unmet medical needs and the potential benefits of GTx-104 have been accepted for presentation at two major medical conferences taking place in March 2026. The Company is participating in an industry education workshop during the Society of Critical Care Medicine's Critic
- PRGrace Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferencePRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen's 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA. Mr. Kohli's presentation is schedule for March 4, 2026 at 10:30 AM Eastern Time. To register for the webcast, click here. An archived replay will
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateFDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Meeting Company Continues Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Submission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine b
GRCE FAQ
5 questionsWhere does GRCE stock trade?
Grace Therapeutics Inc. (GRCE) is listed on NASDAQ.What sector and industry is GRCE in?
Grace Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about GRCE?
Grace Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from TD Cowen: Buy with a $1200.00 price target on 2025-05-02. Recent price targets cluster around $1200.00.What companies are similar to GRCE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GRCE side-by-side with any of them on Quantisnow.How can I track GRCE on Quantisnow?
Quantisnow aggregates Grace Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRCE to receive live email and push alerts on every new disclosure.